Actively Recruiting
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Led by Guangdong Provincial People's Hospital · Updated on 2025-03-12
600
Participants Needed
5
Research Sites
291 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium. Galactosedeficient IgA1, supposed to be produced by Peyer patches in the mucosa-associated lymphoid tissue (MALT), is triggered by exposure to commensal or pathogenic bacteria, involved in the initial step in the pathogenesis of IgAN. Similar to intestinal flora, a disruption in oral flora is closely associated with the occurrence of many malignant tumors and autoimmune diseases. The relationship between oral and throat microflora and the occurrence of IgAN is unclear at present. The aim of the present study was to develop a preliminary model based on mucosa -specific microbes and clinical indicators to facilitate the early diagnosis of IgAN and obtain insights into its treatment.
CONDITIONS
Official Title
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological changes of IgA Nephropathy confirmed by kidney biopsy
- Age 16 to 65 years
- No antibiotics or functional foods (probiotics/prebiotics) used for at least one month before sampling
- No hormone or immunosuppressant treatment in the six months prior to sampling
- No significant changes in diet or medication for at least one month
- No other immune or autoimmune diseases such as systemic lupus erythematosus
- Signed informed consent
You will not qualify if you...
- Type I or type II diabetes
- Pregnancy or menstrual period
- Mental illness or inability to complete follow-up
- Medically diagnosed intestinal diseases like irritable bowel syndrome or inflammatory bowel disease
- Viral hepatitis or other infectious diseases
- Use of laxatives including polyethylene glycol electrolyte dispersant, enemas, or others within one month before specimen collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Sun Yat-sen Memorial Hospital Sun Yat-sen university
Guangzhou, Guangdong, China
Actively Recruiting
2
The Third Affiliated Hospital of Southern Medical University
Guangzhou, Guangdong, China
Actively Recruiting
3
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
4
Guangdong Provincial People's Hospital
Guanzhou, Guangdong, China
Actively Recruiting
5
The First Affiliated Hospital of Sun Yat-sen University
Guanzhou, Guangdong, China
Actively Recruiting
Research Team
X
Xueqing Yu
CONTACT
F
Fengtao Cai
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here